Skip to content

AYALA PHARMACEUTICALS, INC.: 10-Q filed 2012-06-14

What AYALA PHARMACEUTICALS, INC. reported in its quarterly report filed 2012-06-14 (fiscal Q2 2012): 26 published measures, 89 facts as tagged in accession 0001144204-12-034931.

This filing

Form
10-Q (quarterly report)
Filed
2012-06-14
Fiscal period
fiscal Q2 2012
Accession
0001144204-12-034931 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All AYALA PHARMACEUTICALS, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2012-04-303,784,865USD
At 2011-10-315,640,562USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2012-04-3015,580,885USD
At 2011-10-3117,920,275USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2012-04-30-11,796,020USD
At 2012-01-31-11,058,318USD
At 2011-10-31-12,279,713USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2012-02-01 to 2012-04-30-2,401,563USD90
2011-11-01 to 2012-04-30-6,155,882USD182
2002-03-01 to 2012-04-30-41,643,738USD3714
2011-11-01 to 2012-01-31-3,754,319USD92
2011-02-01 to 2011-04-30-9,635,417USD89
2010-11-01 to 2011-04-30-8,878,750USD181

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2011-11-01 to 2012-04-30-2,794,665USD182
2002-03-01 to 2012-04-30-32,460,424USD3714
2010-11-01 to 2011-04-30-3,183,553USD181

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

PeriodValueUnitDays
2011-11-01 to 2012-04-3091,844USD182
2002-03-01 to 2012-04-30241,937USD3714
2010-11-01 to 2011-04-300USD181

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2011-11-01 to 2012-04-301,987,287USD182
2002-03-01 to 2012-04-3035,860,357USD3714
2010-11-01 to 2011-04-304,193,995USD181

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2011-11-01 to 2012-04-30-283,532USD182
2002-03-01 to 2012-04-30-3,394,305USD3714
2010-11-01 to 2011-04-30-191,094USD181

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2012-02-01 to 2012-04-30285,322,425shares90
2011-11-01 to 2012-04-30273,945,902shares182
2011-02-01 to 2011-04-30213,370,738shares89
2010-11-01 to 2011-04-30210,079,887shares181

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

PeriodValueUnitDays
2012-02-01 to 2012-04-300USD90
2011-11-01 to 2012-04-30-346,787USD182
2002-03-01 to 2012-04-30-1,927,260USD3714
2011-02-01 to 2011-04-300USD89
2010-11-01 to 2011-04-30-379,472USD181

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2012-04-3087,252USD
At 2011-10-310USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2011-11-01 to 2012-04-30587,562USD182
2002-03-01 to 2012-04-304,388,207USD3714
2010-11-01 to 2011-04-30420,058USD181

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2012-02-01 to 2012-04-30-3,229,827USD90
2011-11-01 to 2012-04-30-6,474,128USD182
2002-03-01 to 2012-04-30-48,947,358USD3714
2011-02-01 to 2011-04-30-3,408,355USD89
2010-11-01 to 2011-04-30-6,378,002USD181

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2012-04-3064,506USD
At 2011-10-311,614,021USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

PeriodValueUnitDays
2012-02-01 to 2012-04-301,579,626USD90
2011-11-01 to 2012-04-303,196,508USD182
2002-03-01 to 2012-04-3013,645,845USD3714
2011-02-01 to 2011-04-30418,697USD89
2010-11-01 to 2011-04-30951,045USD181

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2012-04-3012,357,573USD
At 2011-10-3110,895,961USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2012-02-01 to 2012-04-303,229,827USD90
2011-11-01 to 2012-04-306,474,128USD182
2002-03-01 to 2012-04-3050,810,701USD3714
2011-02-01 to 2011-04-303,408,355USD89
2010-11-01 to 2011-04-306,378,002USD181

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2012-02-01 to 2012-04-302,215,834USD90
2011-11-01 to 2012-04-304,428,743USD182
2002-03-01 to 2012-04-3027,585,483USD3714
2011-02-01 to 2011-04-302,446,710USD89
2010-11-01 to 2011-04-304,434,401USD181

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2012-04-30287,038,332shares
At 2011-10-31250,173,570shares

Net intangible assets excluding goodwill

Intangible assets other than goodwill after amortization and impairment. Internally developed intangibles are usually not recognized, so this understates what a company relies on.

PeriodValueUnitDays
At 2012-04-302,376,116USD
At 2011-10-312,256,852USD

Net income available to common stockholders

Net income after preferred dividends and similar adjustments, the numerator for basic earnings per share. It can be lower than reported net income.

PeriodValueUnitDays
2012-02-01 to 2012-04-30-2,586,563USD90
2011-11-01 to 2012-04-30-6,525,882USD182
2002-03-01 to 2012-04-30-43,596,308USD3714
2011-02-01 to 2011-04-30-9,815,083USD89
2010-11-01 to 2011-04-30-10,047,436USD181

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2012-02-01 to 2012-04-301,013,993USD90
2011-11-01 to 2012-04-302,045,385USD182
2002-03-01 to 2012-04-3023,225,218USD3714
2011-02-01 to 2011-04-30961,645USD89
2010-11-01 to 2011-04-301,943,601USD181

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

PeriodValueUnitDays
2011-11-01 to 2012-04-304,592USD182
2002-03-01 to 2012-04-30200,264USD3714
2010-11-01 to 2011-04-3019,568USD181

Depreciation, depletion and amortization

Combined depreciation, depletion and amortization for the period. A noncash allocation of asset cost, not a measure of maintenance spending.

PeriodValueUnitDays
2011-11-01 to 2012-04-3072,424USD182
2002-03-01 to 2012-04-30667,064USD3714
2010-11-01 to 2011-04-3065,256USD181

Amortization of intangible assets

Amortization recognized on finite-lived intangible assets. It follows acquisition accounting and does not indicate the intangibles are losing usefulness at that rate.

PeriodValueUnitDays
2011-11-01 to 2012-04-30-191,688USD182
2002-03-01 to 2012-04-30-3,152,368USD3714
2010-11-01 to 2011-04-30-191,094USD181

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

PeriodValueUnitDays
2011-11-01 to 2012-04-300USD182
2002-03-01 to 2012-04-3011,988,230USD3714
2010-11-01 to 2011-04-300USD181

Inspect the source

Entity
AYALA PHARMACEUTICALS, INC. / CIK 0001100397
Captured
SEC response SHA-256
c79571e45bf72206000628dd6d16cc0b78424a189c2c21675f51fe12cd89a549

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001100397.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))